MedTrace Logo

Disseminated Tumour Cells (DTC) in Left Sided Colorectal Cancer (LSCC).

NCT03640572 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 91

Last updated 2019-02-27

No results posted yet for this study

Summary

Two metaanalyses of studies on the prognostic significance of circulating cancer cells in colorectal cancer indicated, that the presence of circulating tumour cells (CTC) in the peripheral blood is the negative prognostic factor. However there is no sufficient evidence that disseminated tumour cells (DTC) in the bone marrow of the colorectal cancer patients influence the prognosis. There is the evidence that right-sided and left- sided cancers may have different biology and different prognosis. Therefore in this study the investigators concentrated on the left colon and rectum locations with the locally advanced cancer being the main area of interest.

The aim of this study was to analyse the relation of DTC with the tumor characteristics, cancer progression and survival in left sided colorectal cancer.

Conditions

Interventions

DIAGNOSTIC_TEST

Bone marrow analysis to identify disseminated tumour cells

Pelleted cells from bone marrow samples were incubated with an excessive amount of lysing solution for 10 min, repeated 3-4 times to remove erythrocytes. The slides were dried, fixed with a mixture of ethanol and acetone (1 : 1 v v-1), and then stained for 30 min with A45-B/B3 monoclonal antibodies (5 μg ml-1) (Micromet GmbH, Germany), which recognise common epitopes of cytokeratins (CK) including CK 8, 18 and 19.

Sponsors & Collaborators

  • Jagiellonian University

    lead OTHER

Principal Investigators

  • Antoni Szczapanik, Assoc. Prof. · Jagiellonian diversity

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-01
Primary Completion
2012-12-31
Completion
2018-12-30

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03640572 on ClinicalTrials.gov